Future Horizons in the European Cancer Diagnostics Market - France, Germany, Italy, Spain, UK: Supplier Shares and Sales Forecasts for 40 Tumor Markers by Country
This report provides a comprehensive analysis of the cancer diagnostics market in five European countries from 2012-2017. It examines trends, reviews current and emerging tests, forecasts sales of 40 tumor markers by country, and profiles leading market players. The market is poised for rapid expansion as technological breakthroughs create new opportunities in genetic testing, tumor detection, and cancer therapy monitoring. An aging population will further increase demand for diagnostic assays and tests. The report is based on 820 pages of analysis and is available for individual purchase at $18,500.
Innovative Cancer Diagnostic Technologies and Emerging MarketsReportsnReports
This document provides a 1200-page report on innovative cancer diagnostic technologies and emerging markets published in November 2012. It identifies business opportunities in the cancer diagnostics market over the next ten years in 7 countries. The report examines trends, reviews current and emerging tests, forecasts sales of tumor markers by country/market, and profiles leading and potential market players. It also evaluates major diagnostic instruments and suggests strategies for suppliers.
Spain Blood Banking Market: Innovative Technologies and Emerging Business Opp...ReportsnReports
This report provides an in-depth analysis of the Spanish blood banking market, including forecasts for test volumes, reagent and instrument sales through 2022. It covers 40 blood typing, grouping, and infectious disease screening tests, along with reviews of current and emerging technologies. The report profiles major suppliers and identifies business opportunities, including opportunities for new instruments, consumables, and products in areas like blood typing, infectious disease screening, and auxiliary products.
2013 Italy Tumor Marker Testing Market: Opportunities and Strategies for Supp...ReportsnReports
This 570-page report provides a comprehensive analysis of the Italian tumor marker testing market, including mortality statistics for major cancer types, forecasts of test volume and sales for over 40 tumor markers through 2022, profiles of leading suppliers, and business opportunities and recommendations. The report covers current and emerging cancer diagnostic technologies, instrumentation used for tumor marker testing, and the impact of economic, regulatory, and other trends on the Italian market over the next decade.
The global monoclonal antibodies market is expected to reach $148.9 billion by 2026, growing at a CAGR of 6.1%. Monoclonal antibodies are primarily used to treat cancer and other chronic diseases. The market is driven by an active drug development pipeline and increasing prevalence of diseases. Key players are focusing on developing biosimilars and targeting new disease areas to capitalize on market opportunities. The cancer segment currently dominates the market due to growing patient numbers and awareness. North America accounts for the largest share of the monoclonal antibodies market.
2013 France Tumor Marker Testing Market: Opportunities and Strategies for Sup...ReportsnReports
This document provides a 430-page market analysis of the 2013 tumor marker testing market in France. It includes 10-year forecasts for test volumes and sales for 40 blood tests. It reviews current instrumentation technologies and analyzers from over 20 suppliers. It also provides profiles of major suppliers and recommendations for business opportunities in the French market. The report is available for purchase for $5,400 for a single-user license and contains detailed tables, charts and analysis of the French blood testing market.
This document provides a commercial market forecast for CAR-T cell therapies in relapsed/refractory chronic lymphocytic leukemia (CLL) across major Western markets through 2030. It includes an executive presentation with over 130 slides and an Excel workbook with detailed forecasts by geographic region and treatment scenario. The document reviews CLL disease background, current treatments, novel immunotherapy approaches including several CAR-T cell therapies in development, and provides a pipeline analysis of key CAR-T programs. It also discusses considerations for pricing and reimbursement of CAR-T cell therapies for CLL and outlines a methodology for forecasting the commercial potential of these therapies between 2017-2030.
European Coagulation Testing Market: Innovative Technologies and Emerging Bus...ReportsnReports
This report provides a comprehensive analysis of the coagulation testing market in five major European countries from 2010-2020. It examines business and technology trends, estimates market sizes and shares by segment and supplier, compares analyzers, and identifies opportunities for suppliers. The growing cost pressures and advancing technologies will change coagulation practice, decentralizing testing and creating new opportunities for quality control products and services closer to patients.
Innovative Cancer Diagnostic Technologies and Emerging MarketsReportsnReports
This document provides a 1200-page report on innovative cancer diagnostic technologies and emerging markets published in November 2012. It identifies business opportunities in the cancer diagnostics market over the next ten years in 7 countries. The report examines trends, reviews current and emerging tests, forecasts sales of tumor markers by country/market, and profiles leading and potential market players. It also evaluates major diagnostic instruments and suggests strategies for suppliers.
Spain Blood Banking Market: Innovative Technologies and Emerging Business Opp...ReportsnReports
This report provides an in-depth analysis of the Spanish blood banking market, including forecasts for test volumes, reagent and instrument sales through 2022. It covers 40 blood typing, grouping, and infectious disease screening tests, along with reviews of current and emerging technologies. The report profiles major suppliers and identifies business opportunities, including opportunities for new instruments, consumables, and products in areas like blood typing, infectious disease screening, and auxiliary products.
2013 Italy Tumor Marker Testing Market: Opportunities and Strategies for Supp...ReportsnReports
This 570-page report provides a comprehensive analysis of the Italian tumor marker testing market, including mortality statistics for major cancer types, forecasts of test volume and sales for over 40 tumor markers through 2022, profiles of leading suppliers, and business opportunities and recommendations. The report covers current and emerging cancer diagnostic technologies, instrumentation used for tumor marker testing, and the impact of economic, regulatory, and other trends on the Italian market over the next decade.
The global monoclonal antibodies market is expected to reach $148.9 billion by 2026, growing at a CAGR of 6.1%. Monoclonal antibodies are primarily used to treat cancer and other chronic diseases. The market is driven by an active drug development pipeline and increasing prevalence of diseases. Key players are focusing on developing biosimilars and targeting new disease areas to capitalize on market opportunities. The cancer segment currently dominates the market due to growing patient numbers and awareness. North America accounts for the largest share of the monoclonal antibodies market.
2013 France Tumor Marker Testing Market: Opportunities and Strategies for Sup...ReportsnReports
This document provides a 430-page market analysis of the 2013 tumor marker testing market in France. It includes 10-year forecasts for test volumes and sales for 40 blood tests. It reviews current instrumentation technologies and analyzers from over 20 suppliers. It also provides profiles of major suppliers and recommendations for business opportunities in the French market. The report is available for purchase for $5,400 for a single-user license and contains detailed tables, charts and analysis of the French blood testing market.
This document provides a commercial market forecast for CAR-T cell therapies in relapsed/refractory chronic lymphocytic leukemia (CLL) across major Western markets through 2030. It includes an executive presentation with over 130 slides and an Excel workbook with detailed forecasts by geographic region and treatment scenario. The document reviews CLL disease background, current treatments, novel immunotherapy approaches including several CAR-T cell therapies in development, and provides a pipeline analysis of key CAR-T programs. It also discusses considerations for pricing and reimbursement of CAR-T cell therapies for CLL and outlines a methodology for forecasting the commercial potential of these therapies between 2017-2030.
European Coagulation Testing Market: Innovative Technologies and Emerging Bus...ReportsnReports
This report provides a comprehensive analysis of the coagulation testing market in five major European countries from 2010-2020. It examines business and technology trends, estimates market sizes and shares by segment and supplier, compares analyzers, and identifies opportunities for suppliers. The growing cost pressures and advancing technologies will change coagulation practice, decentralizing testing and creating new opportunities for quality control products and services closer to patients.
Global & usa cancer immunotherapy market analysis to 2020Research Hub
This document provides an overview and analysis of the global cancer immunotherapy market from 2014 to 2020. It discusses the types of immunotherapies available including monoclonal antibodies, cancer vaccines, and non-specific therapies. It analyzes current trends in immunotherapies such as anti-PD-1 drugs, dendritic cell vaccines, T-cell therapies, and cancer vaccines. It also provides market size data for cancer immunotherapies by geography, indication, company, and individual drugs.
Future Horizons in the UK Cancer Diagnostics Market: Supplier Shares and Sale...ReportsnReports
This 575-page report provides a comprehensive analysis of the UK tumor marker testing market, including 10-year test volume and sales forecasts for 40 tumor markers across hospital, commercial, and physician office market segments. It highlights key issues in UK laboratory practice and analyzes the impact of economic, regulatory, demographic, social, and technological trends. The report also profiles current and emerging suppliers and provides strategic recommendations.
Global cancer stem cell therapy market outlook 2020KuicK Research
“Global Cancer Stem Cell Therapy Market Outlook 2020” Report Highlight:
Introduction & Classification of Stem Cells
Stem Cell Transplants Classification
Cancer Stem Cell Therapy Mechanism of Action
Global Cancer Stem Cell Market Analysis
Global Cancer Stem Cell Clinical Pipeline by Company & Phase
Global Cancer Stem Cell Clinical Pipeline: 32 Therapies
Global Cancer Stem Cell Market Dynamics: Challenges & Favorable Parameters
Global Cancer Stem Cell Market Future Outlook
The Current Oncology Pipeline: Development & LaunchHannah Law
The oncology treatment pipeline over the next four years promises a range of new treatment options across both solid and hematological cancers. There will be over 100 new molecules in phase III development by 2020, with 68% being targeted therapies that will further specialize cancer treatment. This exceptional level of launch activity will increase options for patients but requires healthcare payers and clinicians to better understand treatment pathways and patient populations. The large number of potential new treatments also necessitates reassessing how information about these expanded options is communicated to stakeholders.
Global cancer biosimilars market opportunity outlookKuicK Research
"Global Cancer Biosimilars Market Opportunity Outlook" Report Highlight & Findings:
Introduction & Mechanism of Cancer Biosimilars
Global Cancer Biosimilars Market Dynamics
FDA & EMA Guidelines on Development & Marketing of Biosimilars
Cancer Biosimilars Clinical Pipeline by Company, Indication & Phase
Cancer Biosimilars Clinical Pipeline: 100 Biosimilars
Marketed Cancer Biosimilars Clinical Insight
Marketed Cancer Biosimilars: 15 Biosimilars
Targovax has two immuno-oncology programs, ONCOS and TG, in clinical development. ONCOS is an oncolytic virus that makes cancer antigens visible to the immune system and induces T-cells specific to patients' tumors. TG is a neoantigen vaccine that targets oncogenic RAS mutations and induces T-cells specific to RAS. Targovax has an ongoing clinical program evaluating these programs in several cancer types including melanoma, mesothelioma, ovarian/colorectal, prostate, and pancreatic cancer. Upcoming data readouts are expected in 2018 from ongoing trials in melanoma, pancreatic cancer, and colorectal cancer.
Future Horizons in the Japanese Cancer Diagnostics Market: Supplier Shares an...ReportsnReports
This document provides a 590-page report on the Japanese cancer diagnostics market, including test volume and sales forecasts through 2022 for 40 tumor markers across hospital, commercial, and physician office settings. It highlights key issues in the Japanese laboratory practice and analyzes economic, regulatory, demographic, and technological trends impacting the market. The report also profiles major suppliers and provides strategic recommendations.
Future Horizons in the European Blood Banking Market - France, Germany, Italy...ReportsnReports
This report provides a comprehensive analysis of the blood banking market in 5 European countries over the next 5 years. It includes market size forecasts by test category, estimates of test volumes and instrument placements, and market share of major suppliers by test in each country. The report explores trends in technologies, regulations, automation, and competition that will impact product opportunities for suppliers in blood typing, screening tests, and auxiliary products.
The global immuno-oncology market is expected to reach $38.89 billion by 2025, growing at a CAGR of 21.8%. Immuno-oncology harnesses the immune system to fight cancer through approaches like monoclonal antibodies, therapeutic vaccines, and checkpoint inhibitors. Key drivers are the rising incidence of cancer and advancements in immuno-oncology treatments. Checkpoint inhibitors are currently the largest treatment segment. North America is the largest market due to higher spending on cancer treatments and innovations in immuno-oncology. Major players in the market include Bristol Myers Squibb, Merck, AstraZeneca, and Roche.
Us breast cancer therapy market opportunity analysisRajesh Sarma
"US Breast Cancer Therapy Market Opportunity Analysis" Report Highlight:
US Breast Cancer Incidence & Prevalence
US Breast Cancer Therapy Market Overview
US Breast Cancer Drug Clinical Pipeline by Company & Phase
US Breast Cancer Drug Clinical Pipeline: 251 Drugs
Majority Drugs in Phase-II Trials: 73 Drugs
Marketed Breast Cancer Drugs in US: 32 Drugs
Breast Cancer Patent Analysis
Spain Coagulation Testing Market: Innovative Technologies and Emerging Busin...ReportsnReports
This report provides a comprehensive 398-page analysis of the Spanish coagulation testing market from 2010-2020, including test volume forecasts, placement estimates for automated instrumentation, and sales forecasts for reagents and instruments. It reviews over 50 coagulation analyzers and technologies, profiles major suppliers, and identifies business opportunities. The report is available for $5,400 for a single user license and contains detailed tables on market sizes, test volumes, supplier market shares and instrument placements in Spain.
The document discusses the global market for treatments of castration-resistant prostate cancer (CRPC), which is expected to reach $9.5 billion by 2020. The market is growing due to the limited survival benefits of current treatments and the increasing prevalence of CRPC. Novel breakthrough treatments that demonstrate improved survival outcomes will drive market growth and sales. Untapped markets in Asia, Africa, and Latin America also provide opportunities for future expansion. The report provides an in-depth analysis of the CRPC treatment landscape, pipeline, and market potential through 2020 by therapy type, delivery method, and geography.
This document provides a summary of the Oncology Drug Report 2014, which is described as the world's largest active resource for decision making in oncology. Some key details include:
- It covers 931 active cancer drug developers across 33 countries, along with profiles of 2237 active drugs in development, 37 cancer indications under pipeline analysis, and 523 clinical and 360 preclinical and discovery companies.
- The report is organized across 6 sections and provides comprehensive intelligence on the global oncology drug development landscape, including clinical trials, targets, mechanisms of action, deals and partnerships for individual drugs and companies.
- It aims to help businesses, scientists, investors and clinicians make better decisions by bringing extensive data together in one place
Us biosimilars market opportunity & clinical pipeline analysisRajesh Sarma
“US Biosimilars Market Opportunity & Clinical Pipeline Analysis” Report Highlight:
US Biosimilars Market Introduction
US Biosimilars Regulatory Scenario
Unique Features of US Biosimilars Market
Impact of Biosimilars in US Market
Impact of Reimbursement Policies on US Biosimilars Market
Zarxio: First Approved Biosimilar in US
US Biosimilar Clinical Pipeline By Company, Indication & Phase
US Biosimilar Clinical Pipeline: 104 Biosimilars
Marketed Biosimilars: 1 Biosimilar
The global immuno-oncology market is expected to exceed USD 38.89 billion by 2025, growing at a CAGR of 21.8%. Immuno-oncology or cancer immunotherapy enhances the body's natural defenses to stop cancer growth by using constituents made by the body or in a lab to improve immune system function. Key treatment approaches include monoclonal antibodies, therapeutic vaccines, checkpoint inhibitors, and cytokines while novel targets under investigation include IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, and more. The market is segmented by tumor type and region, with North America currently being the largest market due to high cancer treatment spending and innovation in immuno-oncology treatments.
Dendreon Corporation is developing novel immunotherapies to treat cancer. It has one product, Provenge, approved for late-stage prostate cancer which works by re-engaging the immune system. While showing promise, Provenge faces challenges of high costs, lengthy approval delays, and lawsuits seeking earlier access. Dendreon needs to diversify its pipeline and pursue financing to support clinical trials and market expansion.
Liquid Biopsy Global Market estimated to be worth $8,730.4 million by 2024Vinay Shiva Prasad
The document discusses a report by IQ4I Research & Consultancy on the global liquid biopsy market. Key points include:
- The global liquid biopsy market is estimated to reach $8.7 billion by 2024, driven by rising cancer rates, technological advances, and increased funding. However, high costs and regulatory issues restrain the market.
- The market is segmented by biomarkers, applications, sample type, end-users, and geography. Cell-free DNA leads the biomarkers segment while oncology testing commands the largest application revenue. Blood samples dominate but urine & others are growing.
- North America currently dominates but Asia-Pacific is forecasted to be the fastest growing market due to increasing cancer incidence and awareness in
Ukrainian mining industry outlook – market opportunities and entry strategies...ReportsnReports
Check for Discount on Ukrainian Mining Industry Outlook – Market Opportunities and Entry Strategies, Analyses and Forecasts to 2016 report by BRICdata.
Tax Filing Season: What to Expect and New Opportunities for the Enrollment Co...Enroll America
Slides from a webinar on January 26, 2016. New interactions between health coverage status and taxes continue to be an important piece of the enrollment landscape. Even though the third open enrollment period has minimal overlap with the tax filing season, targeted consumer outreach and education will remain vital to ensuring that current enrollees have a smooth filing process and the remaining uninsured understand the tax implications of being without coverage in 2016. Learn about ways to leverage partnerships with tax-focused groups and see answers to questions about how health coverage relates to tax filing and how to help consumers navigate the process.
Global & usa cancer immunotherapy market analysis to 2020Research Hub
This document provides an overview and analysis of the global cancer immunotherapy market from 2014 to 2020. It discusses the types of immunotherapies available including monoclonal antibodies, cancer vaccines, and non-specific therapies. It analyzes current trends in immunotherapies such as anti-PD-1 drugs, dendritic cell vaccines, T-cell therapies, and cancer vaccines. It also provides market size data for cancer immunotherapies by geography, indication, company, and individual drugs.
Future Horizons in the UK Cancer Diagnostics Market: Supplier Shares and Sale...ReportsnReports
This 575-page report provides a comprehensive analysis of the UK tumor marker testing market, including 10-year test volume and sales forecasts for 40 tumor markers across hospital, commercial, and physician office market segments. It highlights key issues in UK laboratory practice and analyzes the impact of economic, regulatory, demographic, social, and technological trends. The report also profiles current and emerging suppliers and provides strategic recommendations.
Global cancer stem cell therapy market outlook 2020KuicK Research
“Global Cancer Stem Cell Therapy Market Outlook 2020” Report Highlight:
Introduction & Classification of Stem Cells
Stem Cell Transplants Classification
Cancer Stem Cell Therapy Mechanism of Action
Global Cancer Stem Cell Market Analysis
Global Cancer Stem Cell Clinical Pipeline by Company & Phase
Global Cancer Stem Cell Clinical Pipeline: 32 Therapies
Global Cancer Stem Cell Market Dynamics: Challenges & Favorable Parameters
Global Cancer Stem Cell Market Future Outlook
The Current Oncology Pipeline: Development & LaunchHannah Law
The oncology treatment pipeline over the next four years promises a range of new treatment options across both solid and hematological cancers. There will be over 100 new molecules in phase III development by 2020, with 68% being targeted therapies that will further specialize cancer treatment. This exceptional level of launch activity will increase options for patients but requires healthcare payers and clinicians to better understand treatment pathways and patient populations. The large number of potential new treatments also necessitates reassessing how information about these expanded options is communicated to stakeholders.
Global cancer biosimilars market opportunity outlookKuicK Research
"Global Cancer Biosimilars Market Opportunity Outlook" Report Highlight & Findings:
Introduction & Mechanism of Cancer Biosimilars
Global Cancer Biosimilars Market Dynamics
FDA & EMA Guidelines on Development & Marketing of Biosimilars
Cancer Biosimilars Clinical Pipeline by Company, Indication & Phase
Cancer Biosimilars Clinical Pipeline: 100 Biosimilars
Marketed Cancer Biosimilars Clinical Insight
Marketed Cancer Biosimilars: 15 Biosimilars
Targovax has two immuno-oncology programs, ONCOS and TG, in clinical development. ONCOS is an oncolytic virus that makes cancer antigens visible to the immune system and induces T-cells specific to patients' tumors. TG is a neoantigen vaccine that targets oncogenic RAS mutations and induces T-cells specific to RAS. Targovax has an ongoing clinical program evaluating these programs in several cancer types including melanoma, mesothelioma, ovarian/colorectal, prostate, and pancreatic cancer. Upcoming data readouts are expected in 2018 from ongoing trials in melanoma, pancreatic cancer, and colorectal cancer.
Future Horizons in the Japanese Cancer Diagnostics Market: Supplier Shares an...ReportsnReports
This document provides a 590-page report on the Japanese cancer diagnostics market, including test volume and sales forecasts through 2022 for 40 tumor markers across hospital, commercial, and physician office settings. It highlights key issues in the Japanese laboratory practice and analyzes economic, regulatory, demographic, and technological trends impacting the market. The report also profiles major suppliers and provides strategic recommendations.
Future Horizons in the European Blood Banking Market - France, Germany, Italy...ReportsnReports
This report provides a comprehensive analysis of the blood banking market in 5 European countries over the next 5 years. It includes market size forecasts by test category, estimates of test volumes and instrument placements, and market share of major suppliers by test in each country. The report explores trends in technologies, regulations, automation, and competition that will impact product opportunities for suppliers in blood typing, screening tests, and auxiliary products.
The global immuno-oncology market is expected to reach $38.89 billion by 2025, growing at a CAGR of 21.8%. Immuno-oncology harnesses the immune system to fight cancer through approaches like monoclonal antibodies, therapeutic vaccines, and checkpoint inhibitors. Key drivers are the rising incidence of cancer and advancements in immuno-oncology treatments. Checkpoint inhibitors are currently the largest treatment segment. North America is the largest market due to higher spending on cancer treatments and innovations in immuno-oncology. Major players in the market include Bristol Myers Squibb, Merck, AstraZeneca, and Roche.
Us breast cancer therapy market opportunity analysisRajesh Sarma
"US Breast Cancer Therapy Market Opportunity Analysis" Report Highlight:
US Breast Cancer Incidence & Prevalence
US Breast Cancer Therapy Market Overview
US Breast Cancer Drug Clinical Pipeline by Company & Phase
US Breast Cancer Drug Clinical Pipeline: 251 Drugs
Majority Drugs in Phase-II Trials: 73 Drugs
Marketed Breast Cancer Drugs in US: 32 Drugs
Breast Cancer Patent Analysis
Spain Coagulation Testing Market: Innovative Technologies and Emerging Busin...ReportsnReports
This report provides a comprehensive 398-page analysis of the Spanish coagulation testing market from 2010-2020, including test volume forecasts, placement estimates for automated instrumentation, and sales forecasts for reagents and instruments. It reviews over 50 coagulation analyzers and technologies, profiles major suppliers, and identifies business opportunities. The report is available for $5,400 for a single user license and contains detailed tables on market sizes, test volumes, supplier market shares and instrument placements in Spain.
The document discusses the global market for treatments of castration-resistant prostate cancer (CRPC), which is expected to reach $9.5 billion by 2020. The market is growing due to the limited survival benefits of current treatments and the increasing prevalence of CRPC. Novel breakthrough treatments that demonstrate improved survival outcomes will drive market growth and sales. Untapped markets in Asia, Africa, and Latin America also provide opportunities for future expansion. The report provides an in-depth analysis of the CRPC treatment landscape, pipeline, and market potential through 2020 by therapy type, delivery method, and geography.
This document provides a summary of the Oncology Drug Report 2014, which is described as the world's largest active resource for decision making in oncology. Some key details include:
- It covers 931 active cancer drug developers across 33 countries, along with profiles of 2237 active drugs in development, 37 cancer indications under pipeline analysis, and 523 clinical and 360 preclinical and discovery companies.
- The report is organized across 6 sections and provides comprehensive intelligence on the global oncology drug development landscape, including clinical trials, targets, mechanisms of action, deals and partnerships for individual drugs and companies.
- It aims to help businesses, scientists, investors and clinicians make better decisions by bringing extensive data together in one place
Us biosimilars market opportunity & clinical pipeline analysisRajesh Sarma
“US Biosimilars Market Opportunity & Clinical Pipeline Analysis” Report Highlight:
US Biosimilars Market Introduction
US Biosimilars Regulatory Scenario
Unique Features of US Biosimilars Market
Impact of Biosimilars in US Market
Impact of Reimbursement Policies on US Biosimilars Market
Zarxio: First Approved Biosimilar in US
US Biosimilar Clinical Pipeline By Company, Indication & Phase
US Biosimilar Clinical Pipeline: 104 Biosimilars
Marketed Biosimilars: 1 Biosimilar
The global immuno-oncology market is expected to exceed USD 38.89 billion by 2025, growing at a CAGR of 21.8%. Immuno-oncology or cancer immunotherapy enhances the body's natural defenses to stop cancer growth by using constituents made by the body or in a lab to improve immune system function. Key treatment approaches include monoclonal antibodies, therapeutic vaccines, checkpoint inhibitors, and cytokines while novel targets under investigation include IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, and more. The market is segmented by tumor type and region, with North America currently being the largest market due to high cancer treatment spending and innovation in immuno-oncology treatments.
Dendreon Corporation is developing novel immunotherapies to treat cancer. It has one product, Provenge, approved for late-stage prostate cancer which works by re-engaging the immune system. While showing promise, Provenge faces challenges of high costs, lengthy approval delays, and lawsuits seeking earlier access. Dendreon needs to diversify its pipeline and pursue financing to support clinical trials and market expansion.
Liquid Biopsy Global Market estimated to be worth $8,730.4 million by 2024Vinay Shiva Prasad
The document discusses a report by IQ4I Research & Consultancy on the global liquid biopsy market. Key points include:
- The global liquid biopsy market is estimated to reach $8.7 billion by 2024, driven by rising cancer rates, technological advances, and increased funding. However, high costs and regulatory issues restrain the market.
- The market is segmented by biomarkers, applications, sample type, end-users, and geography. Cell-free DNA leads the biomarkers segment while oncology testing commands the largest application revenue. Blood samples dominate but urine & others are growing.
- North America currently dominates but Asia-Pacific is forecasted to be the fastest growing market due to increasing cancer incidence and awareness in
Ukrainian mining industry outlook – market opportunities and entry strategies...ReportsnReports
Check for Discount on Ukrainian Mining Industry Outlook – Market Opportunities and Entry Strategies, Analyses and Forecasts to 2016 report by BRICdata.
Tax Filing Season: What to Expect and New Opportunities for the Enrollment Co...Enroll America
Slides from a webinar on January 26, 2016. New interactions between health coverage status and taxes continue to be an important piece of the enrollment landscape. Even though the third open enrollment period has minimal overlap with the tax filing season, targeted consumer outreach and education will remain vital to ensuring that current enrollees have a smooth filing process and the remaining uninsured understand the tax implications of being without coverage in 2016. Learn about ways to leverage partnerships with tax-focused groups and see answers to questions about how health coverage relates to tax filing and how to help consumers navigate the process.
Dokumen tersebut membahas tentang metode analisis gravimetri khususnya untuk menentukan kadar nikel menggunakan reagen dimetil glikoksime. Langkah-langkah percobaan meliputi pembuatan larutan nikel, penambahan reagen, pembentukan endapan, penyaringan, pengeringan, dan penimbangan endapan untuk dihitung kadar nikel berdasarkan faktor gravimetri.
Local forwarding relaying mode usage modelYi-Hsueh Tsai
1. Concept of Relay
2. Concept of local forwarding relaying
3. Advantages for local forwarding relaying
4. Local forwarding relaying scenarios
5. Summary
This seminar covers design for testability (DfT) principles based on a textbook. It is intended for those involved in manufacturing, design, or testing who want to learn how to design products for easier testing. The seminar covers topics like stress and failure analysis, variation and reliability, design analysis, development testing, manufacturing testing, software testing, and data analysis. It aims to teach participants how to design products that withstand stresses, have reliable electronics and materials, can be easily tested at different stages, and provide useful test data.
S1-153199 Use Case and Requirements for DA2GCYi-Hsueh Tsai
According to ITU-R M.2282-0, a broadband Direct-Air-to-Ground Communications (DA2GC) system constitutes an application for various types of telecommunication services, such as Internet access and mobile multimedia services, during flights. The connection with the flight passengers’ user terminals on board aircraft is realized by already available mobile communication systems on board aircraft. The main application field would be Air Passenger Communications (APC). In addition, a broadband DA2GC system could also support Airline Administrative Communications services (AAC) and thus improve aircraft operation, resulting, in particular, in reduced Operational Expenditure (OPEX) for the airlines. Safety-relevant communications such as Air Traffic Control (ATC) and related services are not intended to be covered. The 5G technology should bring the same broadband wireless access capability for on-board network access to the airlines, and provide almost the same experience in the air that you have at home.
Personal Accident and Health Insurance in Portugal, Key Trends and Opportunit...ReportsnReports
This document provides a detailed market analysis of the personal accident and health insurance industry in Portugal from 2007-2016. It finds that gross written premiums in this segment declined from 2007-2011 due to Portugal's weak economy and sovereign debt crisis. The segment accounted for 10.9% of total insurance premiums in 2011. The report provides historical data and forecasts premiums, distribution channels, competitive landscape, and the impact of regulations on key companies in the industry. It aims to help readers make strategic business decisions and identify growth opportunities within the personal accident and health insurance segment in Portugal.
Turkey Diagnostic Imaging Investment Opportunities, Analysis and Forecasts to...ReportsnReports
The report analyzes the diagnostic imaging market in Turkey from 2004-2018. It provides market size data for 10 categories including CT systems, MRI systems, ultrasound systems and x-ray systems. The 149-page report was published in November 2012 and costs $2,500 for a single user license. It draws data from proprietary databases, primary/secondary research and in-house analysis from industry experts. The report provides revenue, volume and price data for each segment as well as company market shares within Turkey's diagnostic imaging industry.
Discussion on Support Long Range Cell Operation for GCSE (S1-141011)Yi-Hsueh Tsai
In the current GCSE architecture in TR 23.768, it requires to routine all group-cast media transports to the GCSE server in EPC and registers all GCSE members to the GCSE server. Therefore, RP-140185[3] mentions that the required end-to-end delay for media transport may exceed the requirement of 150 ms, and the required time for joining an ongoing group communication may in worse case exceed the requirement of 300 ms. However, by using long-range cell, those issues can be mitigated by two reasons.
1) Comparing with the current GCSE architecture, long-range cell can shorten the required end-to-end delay by local routed the group-cast media transports to the UEs without go back to the GCSE server in order to meet the maximum latency requirement, 150ms.
In TR 23703, it mentions that we have to handle out of network coverage scenarios for proximity direct communication in rural area. Therefore, long-range cell is proposed to reduce network converge holes, and thus the phenomenon can be significantly mitigated especially in the rural area.
Although, for receivers located in the fringe areas outside the coverage contour can only receive outbound communication, those UEs can still obtain synchronization signal, system information block, and semi-persistent resource management information for establishing direct communication.
European Blood Banking Market: Innovative Technologies and Emerging Business ...ReportsnReports
This report provides an in-depth analysis of the European blood banking market between 2012-2017, including test volumes, sales, technologies and major players. It explores trends in France, Germany, Italy, Spain and the UK, forecasting growth in blood typing, infectious disease screening and reagent sales. The 170-page report examines emerging opportunities for new instruments, reagents and IT applications, as the market shifts towards more automation and stringent regulations. During this period the blood banking industry will undergo significant changes presenting business opportunities for current and new market entrants.
A Holiday Retail in Review: Performance Lessons for 2014
Similar to Future Horizons in the European Cancer Diagnostics Market - France, Germany, Italy, Spain, UK: Supplier Shares and Sales Forecasts for 40 Tumor Markers by Country
Global Molecular Diagnostics Market: Innovative Technologies and Emerging Bus...ReportsnReports
This document provides a 1050-page report on the global molecular diagnostics market, published in December 2012. It explores business and technology trends in major markets, provides test volume/sales forecasts, compares diagnostic platforms, and identifies opportunities for instrument and reagent suppliers through 2022. The molecular diagnostics market is growing rapidly as new automated systems and cost-effective products are introduced. Companies must integrate new technology and business strategies to capitalize on emerging opportunities in this field over the next decade.
Innovative Molecular Diagnostic Technologies and Emerging MarketsReportsnReports
This document provides a 1050-page report on innovative molecular diagnostic technologies and emerging markets. It explores business and technology trends in major countries and provides forecasts for market size, test volumes, and shares of leading competitors over the next 5-10 years. The report also profiles leading market players, identifies opportunities in product development, and discusses strategies for companies to successfully capitalize on the growing molecular diagnostics market.
Germany Molecular Diagnostics Market: Innovative Technologies and Emerging Bu...ReportsnReports
This 850-page report provides a comprehensive analysis of the German molecular diagnostics market, including major issues, trends, technologies, test categories, suppliers, and business opportunities. It forecasts test volumes and reagent sales for infectious diseases, genetic diseases, cancer, and other applications over 10 years. The report profiles leading suppliers and identifies over 60 specific product opportunities. It also discusses alternative market entry strategies and potential barriers.
The 2011 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan&...ReportLinker.com
During the next decade, the clinical chemistry and immunodiagnostics markets will undergo significant transformation. The changes will be caused convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments, like routine chemistry, will resemble commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others."The Clinical Chemistry and Immunodiagnostics Markets" is a unique worldwide market intelligence and technology assessment study designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and develop effective strategic responses. The study explores future trends in the U.S., five major European countries and Japan; provides estimates of the specimen, test and sales volumes, as well as major suppliers' sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities facing suppliers during the next ten years.Contains 1,115 pages and 450 tables
2013 US Tumor Marker Testing Market: Opportunities and Strategies for SupplierReportsnReports
This 620-page report provides a comprehensive analysis of the US tumor marker testing market, including cancer statistics, current and emerging diagnostic tests, instrumentation technologies, test volume and sales forecasts through 2023 for various market segments. It highlights major opportunities for suppliers in reagent kits, instrumentation, automation, and software. The report profiles current and emerging suppliers and provides strategic recommendations to support business strategies.
UK Molecular Diagnostics Market: Innovative Technologies and Emerging Busines...ReportsnReports
This 855-page report provides an extensive analysis of the UK molecular diagnostics market, including forecasts of test volumes and reagent sales for infectious diseases, genetic diseases, cancer, and other applications through 2022. It reviews DNA sequencing and probe technologies, detection methods, automated instrumentation, and profiles major suppliers. The report identifies over 60 market opportunities and provides guidance on business strategies, market entry barriers, and alternative market penetration approaches.
Spain Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...ReportsnReports
This 860-page report provides a comprehensive analysis of the molecular diagnostics market in Spain, including key trends, technologies, major applications and suppliers. It covers topics such as DNA sequencing, probe technologies, detection methods, instrumentation, emerging applications in oncology, infectious diseases and pharmacogenomics. The report also identifies over 60 specific business opportunities and strategies for companies to enter the Spanish molecular diagnostics market.
Japan Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...ReportsnReports
This 860-page report provides a comprehensive analysis of the Japanese molecular diagnostics market, including major trends, technologies, applications, and key players. It forecasts test volumes and reagent sales for infectious diseases, genetic diseases, cancer, and other applications. The report profiles leading suppliers and identifies over 60 business opportunities in molecular diagnostic instruments, tests, software, and auxiliary products. It also examines market entry barriers, alternative strategies, and concerns for companies operating in this space.
Innovative Blood Banking Technologies and Emerging MarketsReportsnReports
This report provides an in-depth analysis of the global blood banking market over the next ten years. It explores trends, opportunities, and challenges in blood typing, screening, and related technologies in major countries. The 800-page report profiles competitors, evaluates products/markets, and identifies growth areas. It finds that regulations, automation, and competition will drive significant transformation in the blood banking industry landscape and create new opportunities for instruments, reagents, and IT applications.
Italy Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...ReportsnReports
This 850-page report provides a comprehensive analysis of the Italian molecular diagnostics market, including major issues, trends, technologies, test categories, suppliers, and business opportunities. It forecasts test volumes and reagent sales for infectious diseases, genetic diseases, cancer, forensic testing, and other areas. The report profiles leading suppliers and identifies over 60 market opportunities. It also discusses alternative market strategies, barriers, and competitive landscapes. An executive summary analyzes the Italian business environment and market structure.
France Molecular Diagnostics Market: Innovative Technologies and Emerging Bus...ReportsnReports
This document provides an extensive analysis of the molecular diagnostics market in France, including forecasts of test volumes and reagent sales by application from 2012-2022. It details the major technologies, products, suppliers, and opportunities in the market. The report is 850 pages and provides comprehensive information on DNA sequencing, probe technologies, detection methods, instrumentation, emerging applications in infectious disease, cancer, and genetic testing, as well as profiles of key companies and their products, strategies, and sales. It sells for a single-user license of $5,900.
US Molecular Diagnostics Market: Innovative Technologies and Emerging Busines...ReportsnReports
This 880-page report provides an extensive analysis of the US molecular diagnostics market, including forecasts of test volumes and reagent sales for various applications through 2022. It reviews DNA sequencing and probe technologies, detection methods, automated instrumentation, and profiles major suppliers. The report also identifies over 60 business opportunities in instruments, tests, software, and auxiliary products and discusses strategies for market entry.
France Blood Banking Market: Innovative Technologies and Emerging Business Op...ReportsnReports
This document provides a 430-page report on the blood banking market in France, including forecasts for blood testing volumes and reagent sales over the next 10 years. It covers 40 different blood tests and the major suppliers for those tests. The report also reviews emerging testing technologies and their potential applications, as well as business opportunities and strategic recommendations for suppliers in this market. It provides an in-depth analysis of market drivers, trends, participants and growth opportunities in the French blood banking sector.
Point-of-Care Testing Markets: Innovative Technologies and Emerging Business ...ReportsnReports
This 1007-page report provides a comprehensive analysis of the point-of-care testing market, including market sizing, segmentation, technology trends, and strategic recommendations. It forecasts test volume and sales for segments like cancer clinics, ambulatory care centers, and surgery centers. The report also examines major suppliers, new product opportunities, design criteria for decentralized products, and potential market barriers. It is based on primary and secondary research sources to help diagnostic companies develop effective business and R&D strategies for the growing point-of-care market.
2013 Clinical Chemistry and Immunodiagnostics Markets: Growth Opportunities a...ReportsnReports
This document provides a 1115-page market report on the clinical chemistry and immunodiagnostics markets from 2013-2023. It details test volumes, sales forecasts, and market shares of leading suppliers for 100 assays in the US, Europe and Japan. The markets will undergo significant changes driven by new regulations, diagnostic technologies, automation, and competition. New opportunities will arise for instruments, reagents, and auxiliary products.
This 411-page report from January 2013 analyzes the US hospital coagulation testing market. It provides volume and sales forecasts for 40 coagulation procedures performed in US hospitals through 2018. It reviews current instrumentation technologies and compares leading analyzers. It also profiles major suppliers of reagents and instruments, and identifies business opportunities in the market. The report is available for $6,300 for a single-user license and its table of contents covers topics like coagulation tests, instrumentation, technologies, the US market structure and size, and competitive assessments of major companies.
Future Horizons in the European Molecular Diagnostics Market--France, Germany...ReportLinker.com
This comprehensive five-country report is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years. Contains 970 pages and 75 tables
Diagnostic Testing in Ancillary Hospital Locations: Innovative Technologies a...ReportsnReports
This document provides a 973-page report on diagnostic testing markets outside main hospital laboratories, such as emergency rooms, operating rooms, and intensive care units. It includes analysis of market dynamics, size, growth trends, technologies, and business opportunities. The report segments the market and provides test volume and sales forecasts for over 300 procedures. It also reviews leading point-of-care diagnostic instruments and emerging technologies. Strategic recommendations are provided for new product opportunities and alternative market expansion strategies.
US Blood Banking Market: Innovative Technologies and Emerging Business Opport...ReportsnReports
This report provides a comprehensive analysis of the US blood banking market, including forecasts for blood testing volumes and reagent sales over the next 10 years. It examines key issues, regulations, and trends impacting the market. The report profiles major suppliers and analyzes their market shares, product portfolios, and business strategies. It also reviews emerging technologies with potential applications in blood banking and identifies opportunities for market players.
European Immunodiagnostics Markets: Innovative Technologies and Emerging Busi...ReportsnReports
The 900-page report provides market intelligence on the European immunodiagnostics market, including test volumes, sales, and supplier market shares in five major European countries and Japan. It identifies emerging opportunities for new instruments, reagents, and products in the transforming clinical chemistry and immunodiagnostics markets. The report explores future trends and compares analyzers, profiling competitors. It will help suppliers and potential entrants evaluate opportunities and develop strategic responses to changing regulations, new technologies, and intensifying competition in this evolving marketplace.
Similar to Future Horizons in the European Cancer Diagnostics Market - France, Germany, Italy, Spain, UK: Supplier Shares and Sales Forecasts for 40 Tumor Markers by Country (20)
European Immunodiagnostics Markets: Innovative Technologies and Emerging Busi...
Future Horizons in the European Cancer Diagnostics Market - France, Germany, Italy, Spain, UK: Supplier Shares and Sales Forecasts for 40 Tumor Markers by Country
1. Future Horizons in the European Cancer Diagnostics Market -
France, Germany, Italy, Spain, UK: Supplier Shares and Sales
Forecasts for 40 Tumor Markers by Country
Report Details:
Published:September 2012
No. of Pages: 820
Price: Single User License – US$18500
This unique report provides information not available from any other published source, including
volume, sales, and leading supplier shares by test.This comprehensive five-country report
identifies and evaluates major business opportunities emerging in the cancer diagnostics market
during the next five years; examines trends in France, Germany, Italy, Spain, and the UK; reviews
current and emerging tests; analyzes potential applications of various diagnostic technologies;
forecasts sales of major tumor markers by country and market segment; profiles leading market
players and potential entrants; and suggests alternative business expansion strategies for
suppliers.The cancer diagnostics market is on the verge of explosion, as the researchers
approach major technological breakthroughs in tumor diagnosis and therapy, discover new
specific antigens, and unlock the mystery of the genetic basis of the disease.; During the next five
years, the European cancer diagnostic testing market is promising to be an exciting, dynamic and
rapidly expanding field. Anticipated technological breakthroughs will create numerous
opportunities for determining genetic predisposition, detecting specific tumors, and monitoring
biological response to cancer therapy.; The rise in geriatric population will further compound the
growing demand for malignancy assays and the rapid market expansion.
This unique report provides information not available from any other published source, including
volume, sales, and leading supplier shares by test. This comprehensive five-country report
identifies and evaluates major business opportunities emerging in the cancer diagnostics market
during the next five years; examines trends in France, Germany, Italy, Spain, and the UK; reviews
current and emerging tests; analyzes potential applications of various diagnostic technologies;
forecasts sales of major tumor markers by country and market segment; profiles leading market
players and potential entrants; and suggests alternative business expansion strategies for
suppliers.
The cancer diagnostics market is on the verge of explosion, as the researchers approach major
technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and
unlock the mystery of the genetic basis of the disease. During the next five years, the European
2. cancer diagnostic testing market is promising to be an exciting, dynamic and rapidly expanding
field. Anticipated technological breakthroughs will create numerous opportunities for determining
genetic predisposition, detecting specific tumors, and monitoring biological response to cancer
therapy. The rise in geriatric population will further compound the growing demand for malignancy
assays and the rapid market expansion.
Get your copy of this report @
http://www.reportsnreports.com/reports/192162-future-horizons-in-the-european-cancer-diagnostics-market-
france-germany-italy-spain-uk-supplier-shares-and-sales-forecasts-for-40-tumor-markers-by-country.html
Major points covered in Table of Contents of this report include
Table of Contents
Introduction
Worldwide Market and Technology Overview
A. Cancer Statistics and Etiology
1. Brest Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer
B. Major Current And Emerging Cancer Diagnostic Tests
1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembrionic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
7. 15. J&J Vitros 5600
16. Olympus AU5400
17. Olympus AU3000i
18. Olympus AU2700
19. Roche Modular Analytics
20. Roche Cobas Integra 400
21. Roche Cobas Integra 400 Plus
22. Roche Elecsys
23. Roche Cobas c311
24. Siemens ADVIA Centaur
25. Siemens Dimension
26. Siemens Dimension RxL Max
27. Siemens Dimension Vista 500
28. Siemens Immulite
29. Siemens Stratus
30. Tosoh AIA-Series
31. Vital Diagnostics ATAC 8000
32. Vital Diagnostics Envoy 500
D. Current and Emerging Technologies
1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
a. Technological Principle
b. Radioimmunoassay (RIA)
c. Enzyme Immunoassays (EIA)
Overview
ELISA
Immunofiltration
Particle-Membrane Capture Immunoassay
Enzyme Amplification
d. Fluorescent Immunoassays
e. Luminescence
Chemiluminescence
Bioluminescence
f. Latex Agglutination
g. Immunoprecipitation
H. Affinity Chromatographu
e. Liposome Flow-Injection Immunoassay
3. Molecular Diagnostics
a. Technology Overview
b. Amplification Methods
PCR
DAP-PCR
8. Immuno-PCR
QC-PCR
CAR
DNA
HPA
LCR
NASBA
QBR
SDA
3 SR, and others
4. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas
Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies
a. CT
b. MRI
c. NMR
d. PET
e. Photonics Spectroscopy
France
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers
Germany
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers
Italy
A. Executive Summary
B. Business Environment
9. C. Market Structure
D. Market Size, Growth and Major Suppliers
Spain
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers
U.K.
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers
Major Product Development Opportunities
A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products
Design Criteria for Decentralized Testing Products
Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
1. Marketing Approaches
2. Product Complexity
3. Customer Preference
4. Established Suppliers
5. Emerging Suppliers
6. Major Types of Distributors
7. Market Segmentation Factor
Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
Competitive Profiles
Abbott
AdnaGen
Applied Gene Technologies
11. Targeted Diagnostics & Therapeutics
Tosoh
Veridex
Wako Pure Chemicals
Wallac/PE
Zila
Appendixes
Appendix I: Major Universities and Research Centers Developing Cancer Diagnostic Technology
and Applications
Appendix II: Assumed Currency Exchange Rates
List Of Tables
Tumor Marker Classification
Major Companies Developing or Marketing
ACTH Tests
Major Companies Developing or Marketing
AFP Tests
Major Companies Developing or Marketing
Beta-2 Microglobulin Tests
Major Companies Developing or Marketing
CA 15-3/27.29 Tests
Major Companies Developing or Marketing
CA 19-9 Tests
Major Companies Developing or Marketing
CA 125 Tests
Major Companies Developing or Marketing
Calcitonin Tests
Major Companies Developing or Marketing
CEA Tests
Major Companies Developing or Marketing
Estrogen Receptor Tests
Major Companies Developing or Marketing
Progesterone Receptor Tests
Major Companies Developing or Marketing
Ferritin Tests
Major Companies Developing or Marketing
Gastrin Tests
Major Companies Developing or Marketing
HCG Tests
Major Companies Developing or Marketing
Insulin Tests
12. Major Companies Developing or Marketing
NSE Tests
Major Companies Developing or Marketing
Occult Blood Tests
Major Companies Developing or Marketing
PAP Smear/HPV Tests
Major Companies Developing or Marketing
PAP Tests
Major Companies Developing or Marketing
PSA Tests
Major Companies Developing or Marketing
Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications
In Cancer Diagnosis
Oncogenes Potential Applications
In Cancer Diagnosis
Major Companies Developing or Marketing
Oncogene Tests
Growth Factors Potential Applications
In Cancer Diagnosis
Colony Stimulating Factors Potential
Applications in Cancer Diagnosis
Lymphokines Potential Applications
In Cancer Diagnosis
Immunohistochemical Stains Potential
Applications in Cancer Diagnosis
Executive Summary Table: France, Total Cancer
Diagnostic Test Volume and Sales Forecast
by Market Segment
France, Estimated Cancer Death Rates
Per 100,000 Population
France, Laboratories Performing Tumor
Marker Tests by Market Segment
France, Hospital Laboratories Performing
Tumor Marker Tests by Bed Size
France, Commercial/Private Laboratories
Performing Tumor Markers
by Annual Test Volume
France, Total Tumor Marker Test Volume
Forecast by Market Segment
France, All Market Segments Major Tumor
Marker Test Volume Forecast
13. France, Hospital Laboratories Major Tumor
Marker Test Volume Forecast by Test
France, Commercial/Private Laboratories
Marker Test Volume Forecast
France, Total Tumor Marker Sales Major Tumor
Forecast by Market Segment
France, All Market Segments Major Tumor
Marker Sales Forecast by Test
France, Hospital Laboratories Major Tumor
Marker Sales Forecast by Test
France, Commercial/Private Laboratories Cancer
Diagnostics Market Forecast by Test
France, ACTH Test Volume and Diagnostics Sales
Forecast by Market Segment
France, AFP Test Volume and Diagnostics Sales
Forecast by Market Segment
France, Beta-2 Microglobulin Test Volume
and Diagnostics Sales Forecast
by Market Segment
France, CA 15-3/27.29 Test Volume
and Diagnostics Sales Forecast
by Market Segment
France, CA 19-9 Test Volume and Diagnostics
Sales Forecast by Market
France, CA-125 Test Volume and Diagnostics
Sales Forecast by Market Segment
France, Calcitonin Test Volume and Diagnostics
Sales Forecast by Market Segment
France, Cathepsin Test Volume and Diagnostics
Sales Forecast by Market Segment
France, CEA Test Volume and Diagnostics Sales
Forecast by Market Segment
France, Colon-Specific Antigen Test Volume
And Diagnostics Sales Forecast
by Market Segment
France, Cytokeratins Test Volume
and Diagnostics Sales Forecast
by Market Segment
France, Estrogen Receptor Test Volume
and Diagnostics Sales Forecast
by Market Segment
France, Ferritin Test Volume
14. and Diagnostics Sales Forecast
by Market Segment
France, Gastrin Test Volume
and Diagnostics Sales Forecast
by Market Segment
France, HCG Test Volume and Diagnostics Sales
Forecast by Market Segment
France, Insulin Test Volume
and Diagnostics Sales Forecast
by Market Segment
France, Interferons Test Volume
and Diagnostics Sales Forecast
by Market Segment
France, Interleukins Test Volume
and Diagnostics Sales Forecast
by Market Segment
France, Lymphocyte Subtyping Test Volume
And Diagnostics Sales Forecast
by Market Segment
France, NSE Test Volume and Diagnostics
Sales Forecast by Market Segment
France, Nucleolar Test Volume and Diagnostics
Sales Forecast by Market Segment
France, Occult Blood Test Volume
and Diagnostics Sales Forecast
by Market Segment
France, Oncogenes Test Volume
and Diagnostics Sales Forecast
by Market Segment
France, Pancreatic Oncofetal Antigen
Test Volume and Diagnostics Sales
Forecast by Market Segment
France, PAP Smear Test Volume
and Diagnostics Sales Forecast
by Market Segment
France, Parathyroid Hormone Test Volume
and Diagnostics Sales Forecast
by Market Segment
France, Progesterone Receptor Test Volume
And Diagnostics Sales Forecast
by Market Segment
France, PAP Test Volume and Diagnostics Sales
15. Forecast by Market Segment
France, PSA Test Volume and Diagnostics Sales
Forecast by Market Segment
France, S-100 Protein Test Volume
and Sales Diagnostics Sales Forecast
by Market Segment
France, Serotonin Test Volume
and Diagnostics Sales Forecast
by Market Segment
France, Sialic Acid Test Volume
and Diagnostics Sales Forecast
by Market Segment
France, Squamous Cell Carcinoma Antigen
Test Volume and Diagnostics Sales
Forecast by Market Segment
France, TDT Test Volume and Diagnostics Sales
Forecast by Market Segment
France, Thymidine Kinase Test Volume
And Diagnostics Sales Forecast
by Market Segment
France, Thyroglobulin Test Volume
and Diagnostics Sales Forecast
by Market Segment
France, TPA Test Volume and Diagnostics Sales
Forecast by Market Segment
France, Total Tumor Marker Sales
By Major Suppliers
France, AFP Testing Market Diagnostics
Sales by Major Supplier
France, CA 15-3 Testing Market Diagnostics
Sales by Major Supplier
France, CA 19-9 Testing Market Diagnostics
Sales by Major Supplier
France, CA 125 Testing Market Diagnostics
Sales by Major Supplier
France, CEA Testing Market Diagnostics
Sales by Major Supplier
France, NSE Testing Market Diagnostics
Sales by Major Supplier
France, PAP Testing Market Diagnostics
Sales by Major Supplier
France, PSA Testing Market Diagnostics
16. Sales by Major Supplier
Executive Summary Table: Germany, Total
Tumor Marker Test Volume and Sales Forecast
By Market Segment
Germany, Estimated Cancer Death Rates
Per 100,000 Population
Germany, Laboratories Performing Tumor
Marker Tests by Market Segment
Germany, Hospital Laboratories Performing
Tumor Marker Tests by Bed Size
Germany, Commercial/Private Laboratories
Performing Tumor Markers by Annual
Test Volume
Germany, Total Tumor Marker Test Volume
Forecast by Market Segment
Germany, All Market Segments, Major Tumor
Marker Test Volume Forecast
Germany, Hospital Laboratories,
Major Tumor Marker Test Volume Forecast
by Test
Germany, Commercial/Private Laboratories
Major Tumor Marker Test Volume Forecast
Germany, Physician Offices/Group
Practices Major Tumor Marker
Test Volume Forecast
Germany, Total Tumor Marker Sales
Forecast by Market Segment
Germany, All Market Segments Major Tumor
Marker Sales Forecast by Test
Germany, Hospital Laboratories, Major Tumor
Marker Sales Forecast by Test
Germany, Commercial/Private Laboratories
Major Tumor Marker Sales Forecast by Test
Germany, Physician Offices/Group Practices
Major Tumor Marker Sales Forecast by Test
Germany, ACTH Test Volume and Diagnostics
Sales Forecast by Market Segment
Germany, AFP Test Volume and Diagnostics
Sales Forecast by Market Segment
Germany, Beta-2 Microglobulin Test Volume
And Diagnostics Sales Forecast
by Market Segment
17. Germany, CA-15-3/27.29 Test Volume and
Diagnostics Sales Forecast by Market Segment
Germany, CA-19 Test Volume and Diagnostics
Sales Forecast by Market Segment
Germany, CA 125 Test Volume and Diagnostics
Sales Forecast by Market Segment
Germany, Calcitonin Test Volume
And Diagnostic Sales Forecast
by Market Segment
Germany, Cathepsin Test Volume and Diagnostics
Sales Forecast by Market Segment
Germany, CEA Test Volume and Diagnostics Sales
Forecast by Market Segment
Germany, Chromogranin Test Volume
And Diagnostics Sales Forecast by Market Segment
Germany, Colon-Specific Antigen Test Volume
And Diagnostics Sales Forecast
by Market Segment
Germany, Cytokeratins Test Volume
and Diagnostics Sales Forecast
by Market Segment
Germany, Estrogen Receptor Test Volume
and Diagnostics Sales Forecast
by Market Segment
Germany, Ferritin Test Volume and Diagnostics
Sales Forecast by Market Segment
Germany, Gastrin Test Volume and Diagnostics
Sales Forecast by Market Segment
Germany, HCG, Test Volume and Diagnostics
Sales Forecast by Market Segment
Germany, Insulin Test Volume and Diagnostics
Sales Forecast by Market Segment
Germany, Interferons Test Volume
and Diagnostics Sales Forecast
by Market Segment
Germany, Interleukins Test Volume
and Diagnostics Sales Forecast
by Market Segment
Germany, Lymphocyte Subtyping Test Volume
and Diagnostics Sales Forecast
by Market Segment
Germany, NSE Test Volume and Diagnostics
18. Sales Forecast by Market Segment
Germany, Occult Blood Test Volume
and Diagnostics Sales Forecast
by Market Segment
Germany, Oncogenes Test Volume
and Diagnostics Sales Forecast
by Market Segment
Germany, Pancreatic Oncofetal Antigen
Test Volume and Diagnostics Sales
Forecast by Market Segment
Germany, Pap Smear Test Volume
and Diagnostics Sales Forecast
by Market Segment
Germany, Parathyroid Hormone Test Volume
and Diagnostics Sales Forecast
by Market Segment
Germany, Progesterone Receptor Test Volume
And Diagnostics Sales Forecast
by Market Segment
Germany, PAP Test Volume and Diagnostics
Sales Forecast by Market Segment
Germany, PSA Test Volume and Diagnostics
Sales Forecast by Market Segment
Germany, S-100 Protein Test Volume
and Diagnostics Sales Forecast
by Market Segment
Germany, Serotonin Test Volume
and Diagnostics Sales Forecast
by Market Segment
Germany, Sialic Acid Test Volume
and Diagnostics Sales Forecast
by Market Segment
Germany, Squamous Cell Carcinoma Antigen
Test Volume and Diagnostics Sales Forecast
By Market Segment
Germany, TDT Test Volume and Diagnostics
Sales Forecast by Market Segment
Germany, Thymidine Kinase Test Volume
and Diagnostics Sales Forecast
by Market Segment
Germany, Thyroglobulin Test Volume
and Diagnostics Sales Forecast
19. by Market Segment
Germany, TPA Test Volume and Diagnostics
Sales Forecast by Market Segment
Germany, Total Tumor Marker Sales
By Major Supplier
Germany, AFP Testing Market Diagnostics
Sales by Major Supplier
Germany CA 15-3/27.29 Testing Market
Diagnostics Sales by Major Supplier
Germany CA 19-9 Testing Market Diagnostics
Sales by Major Supplier
Germany, CA 125 Testing Market Diagnostics
Sales by Major Supplier
Germany, CEA Testing Market Diagnostics
Sales by Major Supplier
Germany, PSA Testing Market Diagnostics
Sales by Major Supplier
Executive Summary Table: Italy, Total Tumor
Marker Test Volume and Diagnostics Sales
Forecast by Market Segment
Italy, Estimated Cancer Death Rates
Per 100,000 Population
Italy, Laboratories Performing Tumor
Marker Tests by Market Segment
Italy, Hospital Laboratories Performing
Tumor Marker Tests by Bed Size
Italy, Commercial/Private Laboratories
Performing Tumor Markers
by Annual Test Volume
Italy, Total Tumor Marker Test Volume
Forecast by Market Segment
Italy, All Market Segments Major Cancer
Diagnostic Test Volume Forecast
Italy, Hospital Laboratories Major Tumor
Marker Test Volume Forecast
Italy, Commercial/Private Laboratories
Major Tumor Marker Test Volume Forecast
Italy, Total Tumor Marker Test Market
Forecast by Market Segment
Italy, All Market Segments Major Tumor
Marker Sales Forecast by Test
Italy, Hospital Laboratories Major
20. Tumor Marker Forecast by Test
Italy, Commercial/Private Laboratories
Major Tumor Marker Sales Forecast
by Test
Italy, ACTH Test Volume and Diagnostics
Sales Forecast by Market Segment
Italy, AFP Test Volume and Diagnostics
Sales Forecast by Market Segment
Italy, Beta-2 Microglobulin Test Volume
And Diagnostics Sales Forecast
by Market Segment
Italy, CA 15-3/27.29 Test Volume
and Diagnostics Sales Forecast
by Market Segment
Italy, CA-19-9 Test Volume and Diagnostics
Sales Forecast by Market Segment
Italy, CA 125 Test Volume and Diagnostics
Sales Forecast by Market Segment
Italy, Calcitonin Test Volume and Diagnostics
Sales Forecast by Market Segment
Italy, CEA Test Volume and Diagnostics Sales
Forecast by Market Segment
Italy, Chromogranin Test Volume
And Diagnostics Sales Forecast by Market Segment
Italy, Colon Specific Antigen Test Volume
And Diagnostics Sales Forecast
by Market Segment
Italy, Cytokeratins Test Volume
and Diagnostics Sales Forecast
by Market Segment
Italy, Estrogen Receptor Test Volume
and Diagnostics Sales Forecast
by Market Segment
Italy, Ferritin Test Volume and Diagnostics
Sales Forecast by Market Segment
Italy, Gastrin Test Volume and Diagnostics
Sales Forecast by Market Segment
Italy, HCG Test Volume and Diagnostics
Sales Forecast by Market Segment
Italy, Insulin Test Volume and Diagnostics
Sales Forecast by Market Segment
Italy, Lymphocyte Subtyping Test Volume
21. And Diagnostics Sales Forecast
by Market Segment
Italy, NSE Test Volume and Diagnostics Sales
Forecast by Market Segment
Italy, Occult Blood Test Volume and Diagnostics
Sales Forecast by Market Segment
Italy, Oncogenes Test Volume and Diagnostics
Sales Forecast by Market Segment
Italy, Pancreatic Oncofetal Antigen Test
Volume and Diagnostics Sales Forecast
by Market Segment
Italy, PAP Smear Test Volume
and Diagnostics Sales Forecast
by Market Segment
Italy, Parathyroid Hormone Test Volume
and Diagnostics Sales Forecast
by Market Segment
Italy, Progesterone Receptor Test Volume
and Diagnostics Sales Forecast
by Market Segment
Italy, PAP Test Volume and Diagnostics Sales
Forecast by Market Segment
Italy, PSA Test Volume and Diagnostics Sales
Forecast by Market Segment
Italy, S-100 Test Volume and Diagnostics
Sales Forecast by Market Segment
Italy, Serotonin Test Volume
and Diagnostics Sales Forecast
by Market Segment
Italy, Sialic Acid Test Volume
and Diagnostics Sales Forecast
by Market Segment
Italy, Squamous Cell Carcinoma Antigen Test
Volume and Diagnostics Sales Forecast
by Market Segment
Italy, TDT Test Volume and Diagnostics Sales
Forecast by Market Segment
Italy, Thymidine Kinase Test Volume
and Diagnostics Sales Forecast
by Market Segment
Italy, Thyroglobulin Test Volume
and Diagnostics Sales Forecast
22. by Market Segment
Italy, TPA Test Volume and Diagnostics Sales
Forecast by Market Segment
Italy, Total Tumor Markers
Sales by Major Suppliers
Italy, AFP Testing Market Diagnostics
Sales by Major Supplier
Italy, CEA Testing Market Diagnostics
Sales by Major Supplier
Italy, PSA Testing Market Diagnostics
Sales by Major Supplier
Executive Summary Table: Spain, Total
Tumor Marker Test Volume and Sales
Forecast by Market Segment
Spain, Estimated Cancer Death Rates
Per 100,000 Population
Spain, Laboratories Performing Tumor
Marker Tests by Market Segment
Spain, Hospital Laboratories Performing
Tumor Marker Tests by Bed Size
Spain, Commercial/Private Laboratories
Performing Tumor Markers by Annual Test Volume
Spain, Total Tumor Marker Test Volume
Forecast by Market Segment
Spain, All Market Segment Major Cancer
Diagnostic Test Volume Forecast
Spain, Hospital Laboratories Major Cancer
Diagnostic Test Volume Forecast by Test
Spain, Commercial/Private Laboratories
Major Tumor Marker Test Volume Forecast
Spain, Total Tumor Marker Sales
Forecast by Market Segment
Spain, All Market Segments Major Tumor
Marker Sales Forecast by Test
Spain, Hospital Laboratories Major Tumor
Marker Sales Forecast by Test
Spain, Commercial/Private Laboratories Major
Tumor Marker Sales Forecast by Test
Spain, AFP Test Volume and Diagnostics Sales
Forecast by Market Segment
Spain, Beta-2 Microglobulin Test Volume and
Diagnostics Sales Forecast by Market Segment
23. Spain, CA 15-3 Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, CA 19-9 Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, CA-125 Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, Calcitonin Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, CEA Test Volume and Diagnostics Sales
Forecast by Market Segment
Spain, Colon-Specific Antigen Test Volume
and Diagnostics Sales Forecast
by Market Segment
Spain, Estrogen Receptor Test Volume
and Diagnostics Sales Forecast
by Market Segment
Spain, Ferritin Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, Gastrin Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, HCG Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, Insulin Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, Lymphocyte Subtyping
Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, NSE Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, Occult Blood Test Volume
and Diagnostics Sales Forecast
by Market Segment
Spain, Oncogenes Test Volume
and Diagnostics Sales Forecast
by Market Segment
Spain, Pancreatic Oncofetal Antigen
Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, PAP Smear Test Volume
and Diagnostics Sales Forecast
by Market Segment
Spain, Parathyroid Hormone Test Volume
24. And Diagnostics Sales Forecast
by Market Segment
Spain, Progesterone Receptor
Test Volume and Diagnostics Sales Forecast
by Market Segment
Spain, PAP Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, PSA Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, S-100 Protein Test Volume
And Diagnostics Sales Forecast
by Market Segment
Spain, Serotonin Test Volume
and Diagnostics Sales Forecast
by Market Segment
Spain, Sialic Acid Test Volume
and Diagnostics Sales Forecast
by Market Segment
Spain, Squamous Cell Carcinoma Antigen
Test Volume and Diagnostics Sales Forecast
by Market Segment
Spain, TDT Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, Thymidine Kinase
Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, Thyroglobulin
Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, TPA Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, Total Tumor Marker Sales
by Major Suppliers
Spain, AFP Testing Market Diagnostics
Sales by Major Supplier
Spain, CA 15-3/27.29 Testing Market
Diagnostics Sales by Major Supplier
Spain, 19-9 Testing Market Diagnostics
Sales by Major Supplier
Spain, CA 125 Testing Market Diagnostics
Sales by Major Supplier
Spain, CEA Testing Market Diagnostics
25. Sales by Major Supplier
Spain, PSA Testing Market Diagnostics
Sales by Major Supplier
Executive Summary Table: U.K., Total
Tumor Marker Test Volume and Sales
Forecast by Market Segment
U.K., Estimated Cancer Death Rates
Per 100,000 Population
U.K., Laboratories Performing Tumor
Marker Tests by Market Segment
U.K., Hospital Laboratories Performing
Tumor Marker Tests by Bed Size
U.K., Commercial/Private Laboratories
Performing Tumor Marker Tests
by Annual Test Volume
U.K., Total Tumor Marker Testing Volume
Forecast by Market Segment
U.K., All Market Segments Major
Tumor Marker Test Volume Forecast
U.K., Hospital Laboratories Major
Tumor Marker Test Volume Forecast
by Test
U.K., Commercial/Private Laboratories
Major Tumor Marker Test Volume Forecast
U.K., Total Tumor Marker Sales
Forecast by Market Segment
U.K., All Market Segments Major
Tumor Marker Sales Forecast by Test
U.K., Hospital Laboratories Major
Tumor Marker Sales Forecast by Test
U.K., Commercial/Private Laboratories
Major Tumor Marker Sales Forecast
by Test
U.K., ACTH Test Volume and Diagnostics Sales
Forecast by Market Segment
U.K., AFP Test Volume and Diagnostics Sales
Forecast by Market Segment
U.K., Beta-2 Microglobulin Test Volume
and Diagnostics Sales Forecast
by Market Segment
U.K., CA 15-3/27.29 Test Volume
and Diagnostics Sales Forecast
26. by Market Segment
U.K., CA 19-9 Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., CA-125 Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Calcitonin Test Volume
and Diagnostics Sales Forecast
by Market Segment
U.K., CEA Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Chromogranin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Colon-Specific Antigen Test Volume
And Diagnostics Sales by Market Segment
U.K., Cytokeratins Test Volume
and Diagnostics Sales Forecast
by Market Segment
U.K., Estrogen Receptor Test Volume
and Diagnostics Sales Forecast
by Market Segment
U.K., Ferritin Test Volume
and Diagnostics Sales Forecast
by Market Segment
U.K., Gastrin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., HCG Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Insulin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Lymphocyte Subtyping Test Volume
and Diagnostics Sales Forecast
by Market Segment
U.K., NSE Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Occult Blood Test Volume
and Diagnostics Sales Forecast
by Market Segment
U.K., Oncogenes Test Volume
and Diagnostics Sales Forecast
by Market Segment
U.K., Pancreatic Oncofetal Antigen
Test Volume and Diagnostics
27. Sales Forecast by Market Segment
U.K., PAP Smear Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Parathyroid Hormone
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Progesterone Receptor
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., PAP Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., PSA Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., S-100 Protein Test Volume
and Diagnostics Sales Forecast
by Market Segment
U.K., Serotonin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Sialic Acid Test Volume
and Diagnostics Sales Forecast
by Market Segment
U.K., Squamous Cell Carcinoma Antigen
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., TDT Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Thymidine Kinase
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Thyroglobulin
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., TPA Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Total Tumor Marker Sales
and Market Shares Forecast
U.K., CEA Testing Market Diagnostics
Sales by Major Supplier
U.K., PSA Testing Market Diagnostics
Sales by Major Supplier